Skip to main content Accessibility help

Thrombolytic Treatment of Acute Cerebral Infarction

  • Kathleen M. Burger and Deborah R. Horowitz


Stroke is a common cause of death and disability throughout the world. Acute neurologic deficits due to ischemic injury deserve rapid recognition and diagnosis in order to provide effective therapy. Intravenous tissue plasminogen activator (t-PA) provided to carefully selected patients that can be treated within 3 hours of stroke onset results in improved outcome in these patients. Intra-arterial administration of t-PA within a 6-hour window is performed at several academic centers in patients with middle cerebral and other intracranial artery occlusions based on results of one randomized clinical trial and numerous case reports. Although acute therapy of ischemic stroke has received much attention since the approval of intravenous t-PA, only a small percentage of individuals suffering a stroke actually receive t-PA. This article will review the optimal management of the acute stroke patient and discuss thrombolytic clinical trials that have been completed as well as those that are in progress.


Corresponding author

Please direct all correspondence to: Kathleen M. Burger, DO, Mount Sinai School of Medicine, One Gustave Levy Place Box 1137, New York, NY 10029; Tel: 212-241-9443, Fax: 212-241-4561; E-mail:


Hide All
1.Brown, RD, Whisnant, JP, Sicks, JD, O'Fallon, WM, Wiebers, DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373380.
2.Broderick, J, Brott, T, Kothari, R, et al.The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415421.
3.Morris, D, Schroeder, E. Stroke epidemiology 2-9. Available at: Accessed 06 1, 2005.
4.Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic sttoke: a randomized controlled trial. The Publications Committee fot the Trial of ORG 10172 in Acute Sttoke Treatment (TOAST) Investigators. JAMA. 1998;279:12651272.
5.The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:15691581.
6.Bath, PM, Iddenden, R, Bath, FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke. 2000;31:17701778.
7.Adams, HP Jr, Adams, RJ, Brott, T, et al.Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:10561083.
8.Mohr, JP, Thompson, JL, Lazar, RM, et al.A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:14441451.
9.CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group, Lancet. 1997;349:16411649.
10.Silver, B, Weber, J, Fisher, M, et al.Medical therapy for acute ischemic stroke. Clin Neuropharmacol. 1996:101128.
11.Grotta, J. Combination Therapy Stroke Trial: rt-PA +/− Lebeluzole [abstract]. Stroke. 2000;31:278.
12.Lyden, P. Safety and efficacy of combined clomethiazole and t-PA for acute stroke-class T: a piloty study. Neurology. 2000;54(suppl 3):A88.
13.Sacco, R, Phillips, S, Haley, E, et al.Efficacy and safety of GV150526 in acute stroke: results of the GAIN Americas Trial (glycine antagonist in neuroprotection), Neurology. 2000;54(suppl 3):A87.
14.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:15811587.
15.Donnan, GA, Davis, SM, Chambers, BR, et al.Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996;276:961966.
16.Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial–Italy (MAST-I) Group. Lancet. 1995;346:15091514.
17.Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial–Europe Study Group. N Engl J Med. 1996;335:1451050.
18.Phan, TG, Wijdicks, EF. Intra-arterial thrombolysis for vertebrobasilar circulation ischemia. Crit Care Clin. 1999;15:719742.
19. Brain Attack Coalition Web site. Availabe at: NINDS stroke division. Accessed on 06 1, 2005.
20.Lyden, P, Brott, T, Tilley, B, et al.Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:22202226.
21.Brott, T, Lu, M, Kothari, R, et al.Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998;29:15041509.
22.von Kummer, R, Nolte, PN, Schnittger, H, Thron, A, Ringelstein, EB. Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke. Neuroradiology. 1996;38:3133.
23.Warach, S, Chien, D, Li, W, Ronthal, M, Edelman, RR. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology. 1992;42:17171723.
24.Albers, GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999;30:22302237.
25.Lyden, P. Thrombolytic Therapy For Stroke. Totowa, NJ: Humana Press Inc.; 2001.
26.Shapiro, J, Bessette, M, Levine, SR, Baumlin, K. HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients. Acad Emerg Med. 2003;10:13251328.
27. Foundation for Education and Research in Neurological Emergencies Web site. Available at: Accessed on 06 1, 2005.
28.Cadilhac, DA, Ibrahim, J, Pearce, DC, et al.Multicenter comparison of processes of care between Stroke Units and conventional care wards in Australia. Stroke. 2004;35:10351040.
29.Product information section for Genentech, Inc. In: Physicians Desk Reference. 58th ed. Medical Economics Company Inc. 2004:12971301.
30.Marler, J, Tilley, B, Lu, M, et al., Earlier treatment associated with better outcome in the NINDS tpa stroke study [abstract]. Stroke. 1999;30:244.
31.Kidwell, CS, Saver, JL, Mattiello, J, et al.Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462469.
32.Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28:21092118.
33.Patel, SC, Levine, SR, Tilley, BC, et al.Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:28302838.
34.Tejima, E, Katayama, Y, Suzuki, Y, Kano, T, Lo, EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke. 2001;32:13361340.
35.Demchuk, AM, Tanne, D, Hill, MD, et al.Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474–80.
36.Alvarez-Sabin, J, Molina, CA, Montaner, J, et al.Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke. 2003;34:12351241.
37.Linfante, I, Llinas, RH, Selim, M, et al.Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke. 2002;33:20662071.
38.Tanne, D, Kasner, SE, Demchuk, AM, et al.Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105:16791685.
39.Katzan, IL, Furlan, AJ, Lloyd, LE, et al.Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:11511158.
40.Albers, GW, Bates, VE, Clark, WM, Bell, R, Verro, P, Hamilton, SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:11451150.
41.Hill, M, Woolfendeu, A, Teal, P, et al.Intravenous alteplase for stroke: the Canadian experience. The Stroke Interventionalist. 2000;2:38.
42.Kwiatkowski, TG, Libman, RB, Frankel, M, et al.Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:17811787.
43.Graham, GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34:28472850.
44.Fagan, SC, Morgenstern, LB, Petitta, A, et al.Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883890.
45.Hacke, W, Kaste, M, Fieschi, C, et al.Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:10172105.
46.Hacke, W, Kaste, M, Fieschi, C, et al.Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:12451251.
47.Clark, WM, Wissman, S, Albers, GW, Jhamandas, JH, Madden, KP, Hamilton, S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:20192026.
48.Hacke, W, Donnan, G, Fieschi, C, et al.Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768774.
49.Nedeltchev, K, Arnold, M, Brekenfeld, C, et al.Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke. 2003;34:12301234.
50.Qureshi, Al, Siddiqui, AM, Kim, SH, et al.Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol. 2004;25:322328.
51.Alexandrov, AV, Grotta, JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59;862867.
52.Furlan, A, Higashida, R, Wechsler, L, et al.Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:20032011.
53.Wechsler, LR, Jungreis, CA. Jungreis, Intra-arterial thrombolysis for carotid circulation ischemia. Crit Care Clin. 1999;15:701718.
54.Zeumer, H, Freitag, HJ, Zanella, F, Thie, A, Arning, C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology. 1993;35:159162.
55.Kidwell, CS, Saver, JL, Carneado, J, et al.Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke. 2002;33:717724.
56.Bourekas, EC, Slivka, AP, Shah, R, Sunshine, J, Suarez, JI. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery. 2004;54:3944; discussion 44-46.
57.Brandt, T, von Kummer, R, Muller-Kuppers, M, Hacke, W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke. 1996;27:875881.
58.Ezaki, Y, Tsutsumi, K, Onizuka, M, et al.Retrospective analysis of neurological outcome after intra-arterial thrombolysis in basilar artery occlusion. Surg Neurol. 2003;60:423429; discussion 429-430.
59.Lewandowski, CA, Frankel, M, Tomsick, TA, et al.Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598–6O5.
60.IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35:904911.
61.Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators. Stroke. 1994;25:17551759.
62.Sherman, DG, Atkinson, RP, Chippendale, T, et al.Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. 2000;283:23952403.
63. Dose escalation study of desmoteplase in acute ischemic stroke page. Stroke Internet Directory/Internet Stroke Center Web site. Available at: Accessed 06 1, 2005.
64.Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. The Abciximab in Ischemic Stroke Investigators. Stroke. 2000;31:601609.
65.Abestt Investigators. Effects of abciximab for acute ischemic stroke: final results of Abciximab in Emergent Stroke Treatment Trial (Abestt) Stroke. 2003;34:252.
66.Hacke, W, Albers, G, Al-Rawi, Y, et al.The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2004;36:6673.
67.Qureshi, Al, Pande, RU, Kim, SH, Hanel, RA, Kirmani, JF, Yahia, AM. Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Irvestig Drugs. 2002;3:17291732.
68.Nakano, S, Iseda, T, Yoneyama, T, Kawano, H, Wakisaka, S. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke. 2002;33:28722876.
69.Schumacher, HC, Meyers, PM, Yavagal, DR, et al.Endovascular mechanical thrombectomy of an occluded superior division branch of the left MCA for acute cardioembolic stroke. Cardiovasc lntervent Radiol. 2003;26:305308.
70.Daffertshofer, M, Fatar, M. Therapeutic ultrasound in ischemic stroke treatment: experimental evidence. Eur J Ultrasound. 2002;16:121130.
71.Alexandrov, AV, Molina, CA, Grotta, JC, et al.Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:21702178.
72.Berlis, A, Lutsep, H, Barnwell, S, et al.Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization. Stroke. 2004;35:11121116.

Related content

Powered by UNSILO

Thrombolytic Treatment of Acute Cerebral Infarction

  • Kathleen M. Burger and Deborah R. Horowitz


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.